Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,386.23

46.63 (3.48%)

, JPM

JPMorgan

$111.84

0.1 (0.09%)

11:03
02/13/18
02/13
11:03
02/13/18
11:03

Cramer says Amazon healthcare JV aims to cut out drug distributors, CNBC reports

The recently announced healthcare venture from Amazon (AMZN), Berkshire Hathaway (BRK.A;BRK.B) and JPMorgan (JPM) is aiming to cut out drug distributors like AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK), according to CNBC's Jim Cramer, citing sources. Reference Link

AMZN

Amazon.com

$1,386.23

46.63 (3.48%)

JPM

JPMorgan

$111.84

0.1 (0.09%)

BRK.A

Berkshire Hathaway

$296,500.00

-2440 (-0.82%)

BRK.B

Berkshire Hathaway

$197.51

-1.38 (-0.69%)

ABC

AmerisourceBergen

$96.45

7 (7.83%)

CAH

Cardinal Health

$65.30

-2.73 (-4.01%)

MCK

McKesson

$146.45

-2.57 (-1.72%)

  • 21

    Feb

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 18

    Mar

  • 13

    Apr

  • 30

    May

  • 13

    Jul

  • 12

    Oct

AMZN Amazon.com
$1,386.23

46.63 (3.48%)

02/13/18
MACQ
02/13/18
NO CHANGE
Target $1750
MACQ
Outperform
Amazon's Twitch aggregate viewership continues to rise, says Macquarie
Macquarie analyst Benjamin Schachter says Amazon's (AMZN) Twitch aggregate viewership continues to rise, and Twitch is now bigger than CNN (TWX). While eSports as a whole is becoming a more concrete opportunity, the analyst notes that which games and genres will be the most popular/viewed eSports over time is unclear. Schachter also highlights that the Overwatch League launched to peak views of over 408K and over 10M unique viewers across the opening week, and that display ads on Amazon properties like Twitch are meaningful contributors to Other revenue, which grew 58% to $4.65B in 2017. He reiterates an Outperform rating and $1,750 price target on Amazon's shares.
02/13/18
WELS
02/13/18
NO CHANGE
WELS
AmerisourceBergen acquisition by Walgreens makes sense, says Wells Fargo
Commenting on The Wall Street Journal report saying Walgreens (WBA) has approached AmerisourceBergen (ABC) in a takeover attempt and the companies remain early in their discussions, Wells Fargo analyst Peter Costa tells investors he believes the acquisition makes sense given the already existing long-term partnership and limited ability to merge laterally. Further, the analyst believes a potential combination could help lower costs and wring out synergies in the U.S. drug distribution channel, and better position Walgreens in the face of increasing competitive threat from a possible Amazon (AMZN) entry. However, a merger might risk alienating AmerisourceBergen's retail pharmacy customers that compete with Walgreens' pharmacies, he contends.
02/13/18
DADA
02/13/18
NO CHANGE
Target $1800
DADA
Buy
Amazon.com investors should take advantage of pullback, says DA Davidson
DA Davidson analyst Tom Forte keeps his Buy rating and $1,800 on Amazon.com but says that investors should take advantage of the latest pullback to add to their positions. In addition to valuation, Forte cites the press reports on the latest hiring of Jennifer Salke as the new head of Amazon Studios, thereby filling "an important void after a potential period of disruption" and bringing one of its most significant areas of investment - proprietary content - back on track. The analyst notes that among Salke's prior accomplishments as the President of NBC Entertainment were hit shows such as "This Is Us", "Glee", "Modern Family", and "Prison Break".
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
JPM JPMorgan
$111.84

0.1 (0.09%)

02/05/18
BWSF
02/05/18
NO CHANGE
Target $194
BWSF
Sell
LendingTree lost JPMorgan as mortgage lending customer, says BWS Financial
BWS Financial analyst Hamed Khorsand reports that LendingTree (TREE) has lost JPMorgan Chase (JPM) as a mortgage lending customer, calling it the company's second "high-profile" mortgage lender loss in about a quarter. The loss of JPMorgan matters both because of how many loans it originates but also due to the read-through that the loss has on the concept of LendingTree's calling center adding value for the lender, according to Khorsand, who keeps a Sell rating and $194 price target on LendingTree shares.
02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/18
KBWI
02/13/18
UPGRADE
Target $127
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded JPMorgan to Outperform with an unchanged price target of $127. The analyst views the recent pullback in the shares as a buying opportunity.
02/12/18
KBWI
02/12/18
UPGRADE
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
BRK.A Berkshire Hathaway
$296,500.00

-2440 (-0.82%)

01/31/18
CHLM
01/31/18
NO CHANGE
CHLM
Amazon consortium could be longer-term health care disruptor, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich says that Amazon (AMZN), Berkshire Hathaway (BRK.A; BRK.B), and JPMorgan (JPM) new company focused initially on technology solutions to provide simplified, high-quality, and transparent healthcare for their employees and families at a reasonable cost could be a longer-term health care disruptor but it may a little premature to jump to conclusions.
02/05/18
BERN
02/05/18
NO CHANGE
BERN
More pronounced risks to drug supply chain from Amazon coalition, says Bernstein
Bernstein analyst Lance Wilkes thinks the risks to the drug supply chain from Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) healthcare joint venture are much more pronounced than risks to traditional MCOs. The analyst thinks the coalition could acquire a transparency PBM, effectively creating an employer PBM Co-op.
01/31/18
FBCO
01/31/18
NO CHANGE
FBCO
No impact on pharma/biotech from Amazon/JPM/Berkshire coalition, says Credit Suisse
Commenting on the news that Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) are partnering to offer healthcare services to their employees, Credit Suisse analyst Vamil Divan says he does not anticipate any impact on the pharmaceutical or biotechnology sectors in the near or immediate term. However, he acknowledged that the biopharma pricing and distribution models include some perverse incentives that could be ripe for potential disruption.
01/31/18
BERN
01/31/18
NO CHANGE
BERN
Bernstein not expecting Amazon/JPMorgan/Berkshire coalition to become insurer
Bernstein analyst Lance Wilkes notes that Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) announced a plan to partner to offer healthcare services to their employees. The analyst does not expect this coalition or new company to become a health insurer, or to create meaningful disruption in core functions of the MCO. Wilkes thinks these three companies will create a new company that will focus on address four high impact areas of healthcare, namely shift to value based care, pharmacy costs, keeping people health/population health management, and consumer engagement. While he believes the retail pharmacy effort of Amazon would not be housed in this coalition, Wilkes argues that this new company may contract with a to-be-developed Amazon online pharmacy.
BRK.B Berkshire Hathaway
$197.51

-1.38 (-0.69%)

ABC AmerisourceBergen
$96.45

7 (7.83%)

02/13/18
JEFF
02/13/18
NO CHANGE
Target $93
JEFF
Buy
Walgreens deal for AmerisourceBergen would be 'headscratcher,' says Jefferies
Jefferies analyst Brian Tanquilut says that while Walgreens Boots Alliance (WBA) acquiring AmerisourceBergen (ABC) would be accretive to earnings, it would be a "headscratcher" for investors. The companies already have a joint venture that affords both the strategic value that combining would provide, Tanquilut tells investors in a research note after the Wall Street Journal reported that Walgreens approached AmerisourceBergen a few weeks ago. The analyst has a Buy rating on Walgreens with a $93 price target. He adds that the potential deal would allow Walgreens to further expand its U.S. business.
02/13/18
LEER
02/13/18
NO CHANGE
LEER
Walgreens may seek to acquire AmerisourceBergen sooner than expected, says Leerink
Leerink analyst David Larsen notes that The Wall Street Journal reported that Walgreens (WBA) has approached AmerisourceBergen (ABC) about a potential takeover. The analyst is surprised that talks of such a large transaction have surfaced so quickly following the Rite Aid (RAD) deal, but says he has always believed that Walgreens at some point would seek to acquire either Express Scripts (ESRX) or AmerisourceBergen. Given the broad-based speculation in the business press about this deal, it is possible shares of Express Scripts will trade off, Larsen contends.
02/13/18
LOOP
02/13/18
NO CHANGE
Target $90
LOOP
Buy
AmerisourceBergen acquisition by Walgreens would model U.K., says Loop Capital
Loop Capital analyst Andrew Wolf believes that a Walgreens (WBA) and AmerisourceBergen (ABC) full merger would have similar attributes to that of the vertically integrated pharmacy model that Walgreens operates in the U.K. If completed, this transaction would come sooner than the analyst would have anticipated likely spurred by the rapid changes in pharmacy and healthcare occurring around Walgreens. Ultimately, Wolf views this strategic response positively as it would better position a combined company to navigate in the face of industry change and possibly even as a disrupter. He reiterates a Buy rating and $90 price target on Walgreens' shares.
CAH Cardinal Health
$65.30

-2.73 (-4.01%)

11/30/17
JEFF
11/30/17
NO CHANGE
JEFF
Jefferies sees drugstore sentiment improving with no Amazon news
Investors were anticipating an announcement from Amazon.com (AMZN) regarding a pharmacy strategy around Thanksgiving due to recent media reports and the resulting sell-side speculation, Jefferies analyst Brian Tanquilut tells investors in a research note. With no Amazon pharmacy entry announced one week removed from the holiday, the analyst believes investor sentiment over the drug supply chain may gradually improve, at least in the near-term. He notes that the price-to-earnings multiples of Walgreens Boots Alliance (WBA) and CVS Health (CVS) have already declined amid speculation of an Amazon entry. Tanquilut acknowledges, however, that the Amazon overhang will not completely go away. The analyst has Buy ratings on UnitedHealth (UNH) and Walgreens, and Hold ratings on AmerisourceBergen (ABC), Cardinal Health (CAH), CVS and McKesson (MCK).
01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
12/04/17
LEER
12/04/17
NO CHANGE
LEER
Amazon entry into healthcare markets focused on medical supplies, says Leerink
Leerink analyst David Larsen says that his recent research around Amazon's (AMZN) licensing activity has shown that the company's entry into healthcare markets is, at least for now, focused on medical supplies and devices rather than pharmaceuticals. The analyst believes Owens & Minor (OMI), Cardinal Health (CAH) and Henry Schein (HSIC) are most exposed but that it will take several years for Amazon Business to scale up manufacturer supply relationships to take significant share. Although the top and bottom line impact may be small over the next year or two, Larsen remains cautious on the group as multiples continue to reflect the Amazon threat as well as pricing and volume headwinds.
12/04/17
DBAB
12/04/17
INITIATION
Target $64
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Cardinal Health with a Hold rating and $64 price target. The analyst believes uncertainty around drug pricing and the potential for integration risk with Cordis and the Patient Recovery acquisitions warrant a "more prudent approach" to the shares.
MCK McKesson
$146.45

-2.57 (-1.72%)

01/23/18
NEED
01/23/18
NO CHANGE
Target $180
NEED
Buy
McKesson price target raised to $180 from $173 at Needham
Needham analyst Kevin Caliendo raised his price target on McKesson to $180 and kept his Buy rating ahead of the company's Q3 earnings next week. The analyst expects McKesson to update on the impact of U.S. corporate tax changes on earnings, anticipating it to be a net positive with a forward rate below the currently projected 24% in FY18.
01/24/18
JEFF
01/24/18
UPGRADE
Target $205
JEFF
Buy
McKesson upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded McKesson to Buy and raised his price target for the shares to $205 from $165. The combination of stabilizing generic drug pricing, a discounted valuation relative to peers and higher earnings estimates due to tax reform will "boost investor interest this year and push the stock's multiple to more appropriate levels," Tanquilut tells investors in a research note. He sees 20% upside from current share levels.
01/24/18
01/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Buy from Hold at Jefferies analyst Brian Tanquilut saying the combination of stabilizing generic drug pricing, a discounted valuation relative to peers and higher earnings estimates due to tax reform will "boost investor interest this year and push the stock's multiple to more appropriate levels." 2. Cree (CREE) upgraded to Hold from Sell at Williams Capital. 3. 3M (MMM) upgraded to Buy from Neutral at Hilliard Lyons with analyst Spencer Joyce saying he sees as a tactical opportunity ahead of its earnings report as he expects estimates to rise following the company's fourth quarter earnings release. 4. Energen (EGN) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Evan Calio saying he expects oil markets to tighten and gas to remain weak in 2018. 5. Capital City Bank (CCBG) was upgraded to Outperform from Market Perform at Hovde Group and to Hold from Sell at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
COWN
02/12/18
NO CHANGE
COWN
Recent pullback in drug distributors a buying opportunity, says Cowen
Cowen analyst Charles Ryhee said the recent pullback in drug distributors is unwarranted given the space's improving underlying fundamentals. He said the core distribution business is seeing stable generic pricing for both buy-side and sell-side and he believes concerns regarding likely proposed Medicare Part B changes are overblown. Ryhee reiterated his Outperform rating on both McKesson (MCK) and AmerisourceBergen (ABC) shares.

TODAY'S FREE FLY STORIES

JKHY

Jack Henry

$121.95

1.79 (1.49%)

12:59
02/24/18
02/24
12:59
02/24/18
12:59
Conference/Events
Jack Henry management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

PFBC

Preferred Bank

$64.05

0.86 (1.36%)

12:52
02/24/18
02/24
12:52
02/24/18
12:52
Conference/Events
Preferred Bank management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

  • 24

    Sep

R

Ryder

$74.54

0.19 (0.26%)

12:47
02/24/18
02/24
12:47
02/24/18
12:47
Conference/Events
Ryder management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ASPU

Aspen Group

$8.85

1.48 (20.08%)

12:29
02/24/18
02/24
12:29
02/24/18
12:29
Conference/Events
Aspen Group to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

TWTR

Twitter

$32.66

0.55 (1.71%)

, AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

10:47
02/24/18
02/24
10:47
02/24/18
10:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWTR

Twitter

$32.66

0.55 (1.71%)

AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

RGR

Sturm, Ruger

$49.90

0.9 (1.84%)

X

U.S. Steel

$43.52

0.54 (1.26%)

STLD

Steel Dynamics

$47.47

-0.53 (-1.10%)

NUE

Nucor

$66.94

-0.01 (-0.01%)

AKS

AK Steel

$5.50

-0.12 (-2.14%)

AET

Aetna

$175.55

0.49 (0.28%)

ANTM

Anthem

$235.24

1.56 (0.67%)

CNC

Centene

$100.45

0.96 (0.96%)

CI

Cigna

$194.79

2.89 (1.51%)

HNT

Health Net

HUM

Humana

$271.19

3.38 (1.26%)

MOH

Molina Healthcare

$72.94

1.38 (1.93%)

UNH

UnitedHealth

$230.16

3.07 (1.35%)

WCG

WellCare

$192.05

0.03 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 07

    Mar

  • 13

    Mar

  • 16

    Apr

  • 30

    May

DBX

Dropbox

, SNAP

Snap

$17.45

-0.06 (-0.34%)

09:49
02/24/18
02/24
09:49
02/24/18
09:49
Periodicals
Dropbox IPO bodes well, Barron's says »

In a follow-up article…

DBX

Dropbox

SNAP

Snap

$17.45

-0.06 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

IPG

Interpublic Group

$24.24

0.3 (1.25%)

, OMC

Omnicom

$77.31

0.52 (0.68%)

09:42
02/24/18
02/24
09:42
02/24/18
09:42
Periodicals
Advertising companies cheaper than usual, Barron's says »

After a tumble last year,…

IPG

Interpublic Group

$24.24

0.3 (1.25%)

OMC

Omnicom

$77.31

0.52 (0.68%)

PUBGY

Publicis

$18.82

0.09 (0.48%)

WPP

WPP

$95.30

0.93 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 05

    Mar

MSFT

Microsoft

$94.06

2.33 (2.54%)

, INTC

Intel

$47.73

1.93 (4.21%)

09:36
02/24/18
02/24
09:36
02/24/18
09:36
Periodicals
Quantum computing soon to be reality, Barron's says »

Microsoft (MSFT) predicts…

MSFT

Microsoft

$94.06

2.33 (2.54%)

INTC

Intel

$47.73

1.93 (4.21%)

NVDA

Nvidia

$245.93

3.78 (1.56%)

MU

Micron

$46.53

2.28 (5.15%)

GOOG

Alphabet

$1,126.79

20.16 (1.82%)

GOOGL

Alphabet Class A

$1,128.09

18.19 (1.64%)

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

09:26
02/24/18
02/24
09:26
02/24/18
09:26
Periodicals
Many downsides when Amazon's HQ2 comes to town, Barron's says »

As Amazon decides on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$0.27

0.0027 (1.02%)

17:43
02/23/18
02/23
17:43
02/23/18
17:43
Hot Stocks
Gabriele Cerrone reports 7.0% stake in ContraVir Pharma, may seek board changes »

The shares of common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

17:41
02/23/18
02/23
17:41
02/23/18
17:41
Periodicals
VW settles U.S. diesel suit just before trial, Reuters reports »

Volkswagen's U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$153.99

3.2 (2.12%)

17:40
02/23/18
02/23
17:40
02/23/18
17:40
Hot Stocks
Breaking Hot Stocks news story on IAC »

Barry Diller reports 8.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SPG

Simon Property

$156.66

2.63 (1.71%)

17:37
02/23/18
02/23
17:37
02/23/18
17:37
Syndicate
Breaking Syndicate news story on Simon Property »

Simon Property files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$28.64

0.99 (3.58%)

17:35
02/23/18
02/23
17:35
02/23/18
17:35
Hot Stocks
Fabrinet director Frank Levinson buys 10,000 shares of company stock »

Frank Levinson, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 12

    Mar

  • 29

    Mar

CASI

Casi Pharmaceuticals

$3.85

0.1 (2.67%)

17:33
02/23/18
02/23
17:33
02/23/18
17:33
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

, TNDM

TNDM

17:31
02/23/18
02/23
17:31
02/23/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Dexcom, TNDM »

DexCom reports 5.6%…

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

TNDM

TNDM

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

  • 04

    Mar

IDXX

Idexx Laboratories

$187.61

3.75 (2.04%)

17:24
02/23/18
02/23
17:24
02/23/18
17:24
Hot Stocks
Idexx Laboratories director sells 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

CYDY

CytoDyn

$0.72

0.02 (2.86%)

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Syndicate
Breaking Syndicate news story on CytoDyn »

CytoDyn files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.